Lung/Colon Cancer Outcomes--Cancer Research Network

肺癌/结肠癌结果--癌症研究网络

基本信息

批准号：
7687728
负责人：
JANE C. WEEKS
金额：
$ 9.35万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
起止时间：
2001-09-18 至 2010-08-31
项目状态：
已结题

项目摘要

We will accrue all patients with newly diagnosed lung or colon cancer receiving their care in one of five geographically diverse sites in the Cancer Research Network, an NCI-funded research consortium of HMOs. Automated data for all patients (2,058 patients with lung cancer over the two year enrollment period, and 1,732 patients with colon cancer over the two year enrollment period) will be supplemented with data obtained from complete medical record review and patient surveys for a sample of 1,424 patients with newly diagnosed lung cancer and 1,222 patients with newly diagnosed colon cancer. We will oversample African-Americans, Asians and Pacific Islanders, as well as Medicaid recipients. In addition, we will assemble an inception cohort of patients with newly diagnosed metastatic recurrences of colorectal cancer during the two-year enrollment period (projected at approximately 300 patients) for comprehensive data collection. We propose to lead analyses of CanCORS-wide core data in order to (1) examine the effect of race and ethnicity on patterns of care, treatment choice, quality of life, symptom control, and satisfaction; (2) characterize the types of providers seen by patients and examine the associations between provider characteristics/attitudes and patterns of care and outcomes; (3) evaluate the relationship between the structure/function of cancer care in the health care delivery systems of participating patients and patient outcomes, including health status, patient satisfaction, and cost; and (4) generate estimates of utility weights and time- and out-of-pocket costs that are disease- and treatment-specific for use in future cost-effectiveness analyses. Finally, in a Special Research Study we will aggregate cost data for CRN CanCORS subjects in order to (1) determine cancer-attributable phase-specific and lifetime costs of care for colorectal and lung cancer; (2) determine the proportion of total cancer-attributable costs that are spent on initial therapy versus second- and third line therapies for each cancer, stratified by stage at diagnosis; and (3) determine the relationship between type of initial therapy and the subsequent lifetime cancer-attributable costs of care.

我们将让所有新诊断出的肺癌或结肠癌患者在癌症研究网络（NCI 资助的 HMO 研究联盟）的五个不同地理位置之一中接受护理。所有患者的自动化数据（两年入组期间 2,058 名肺癌患者，以及两年入组期间 1,732 名结肠癌患者）将补充从完整病历审查和对 1,424 名患者进行的样本调查中获得的数据新诊断肺癌患者和1,222名新诊断结肠癌患者。我们将对非裔美国人、亚洲人和太平洋岛民以及医疗补助受益人进行过度抽样。此外，我们将在两年的入组期内收集新诊断的结直肠癌转移性复发患者的初始队列（预计约 300 名患者），以进行全面的数据收集。我们建议对 CanCORS 范围内的核心数据进行分析，以便 (1) 检查种族和民族对护理模式、治疗选择、生活质量、症状控制和满意度的影响； (2) 描述患者就诊的提供者类型，并检查提供者特征/态度与护理模式和结果之间的关联； (3) 评估参与患者的医疗保健服务系统中癌症护理的结构/功能与患者结果之间的关系，包括健康状况、患者满意度和成本； (4) 生成针对特定疾病和治疗的效用权重以及时间和自付费用的估计，以用于未来的成本效益分析。最后，在一项特别研究中，我们将汇总 CRN CanCORS 受试者的成本数据，以便 (1) 确定结直肠癌和肺癌的癌症可归因的特定阶段和终生护理成本； (2) 确定每种癌症的初始治疗与二线和三线治疗所花费的癌症总费用的比例，并按诊断时的阶段进行分层； (3) 确定初始治疗类型与随后终生癌症相关护理费用之间的关系。

项目成果

期刊论文数量（2）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.

接受晚期非小细胞肺癌化疗的老年人的不良事件。

DOI：
发表时间：
2010-02-01
期刊：
影响因子：
0
作者：
Chrischilles, Elizabeth A;Pendergast, Jane F;Kahn, Katherine L;Wallace, Robert B;Moga, Daniela C;Harrington, David P;Kiefe, Catarina I;Weeks, Jane C;West, Dee W;Zafar, S Yousuf;Fletcher, Robert H
通讯作者：
Fletcher, Robert H

Disclosure control using partially synthetic data for large-scale health surveys, with applications to CanCORS.

使用部分合成数据进行大规模健康调查的披露控制，并应用于 CanCORS。